Johnson & Johnson vs. Eli Lilly: Reliable Stability vs. Rapid Revenue Growth

Johnson & Johnson maintains steady but modest revenue growth with strong dividend yields and diversified operations, while Eli Lilly demonstrates rapid revenue expansion driven by blockbuster diabetes and obesity drugs Mounjaro and Zepbound. Eli Lilly's revenue has nearly doubled over two years, narrowing the gap with J&J, though investors should monitor patent expiration risks and product concentration for both companies.